Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
复制标题
DOI：
10.1080/19420862.2017.1392425
复制
发表时间：
2018-01
期刊：
影响因子：
5.3
通讯作者：
Brusselle G
中科院分区：
文献类型：
--
作者：
Godar M;Blanchetot C;de Haard H;Lambrecht BN;Brusselle G
哮喘影响着全球3亿多人，并带来了巨大的社会经济负担，尤其是在5% - 10%的重度哮喘患者中。到目前为止，临床试验中每一种新的生物制剂的出现都让人们对治疗所有类型的重度哮喘寄予厚望，但只有当这种生物制剂作为附加治疗针对特定的患者亚群时，才取得了成功。事实上，我们现在认识到哮喘是一种具有多种表型的异质性疾病，这些表型基于不同的病理生理机制，被称为内型。因此，哮喘治疗正逐渐转向个性化医疗方法，根据生物标志物确定个体的哮喘内型来定制治疗方案。在此，我们综述了正在进行临床试验或已获批的用于治疗重度2型哮喘的抗体相关疗法的临床疗效。靶向2型细胞因子的生物制剂已显示出稳定的疗效，尤其是在有2型炎症证据的患者中，这表明哮喘生物制剂的未来充满希望。
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe asthma forms, but the outcome has only been successful if the biologic, as add-on treatment, targeted specific patient subgroups. Indeed, we now realize that asthma is a heterogeneous disease with multiple phenotypes, based on distinct pathophysiological mechanisms, called endotypes. Thus, asthma therapy is gradually moving to a personalized medicine approach, tailored to individual's asthma endotypes identified through biomarkers. Here, we review the clinical efficacy of antibody-related therapeutics undergoing clinical trials, or those already approved, for the treatment of severe type 2 asthma. Biologics targeting type 2 cytokines have shown consistent efficacy, especially in patients with evidence of type 2 inflammation, suggesting that the future of asthma biologics is promising.
登录
查看更多内容
DOI：
10.1084/jem.20062211
发表时间：
2007-02-19
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Allakhverdi Z;Comeau MR;Jessup HK;Yoon BR;Brewer A;Chartier S;Paquette N;Ziegler SF;Sarfati M;Delespesse G
通讯作者：
Delespesse G
影响因子：
24.3
作者：
Chung, Kian Fan;Wenzel, Sally E.;Teague, W. Gerald
通讯作者：
Teague, W. Gerald
影响因子：
120.7
作者：
Bachert, Claus;Mannent, Leda;Sutherland, E. Rand
通讯作者：
Sutherland, E. Rand
DOI：
10.1164/rccm.201103-0396oc
发表时间：
2011-11-15
影响因子：
24.7
作者：
Castro, Mario;Mathur, Sameer;Nair, Parameswaran
通讯作者：
Nair, Parameswaran
影响因子：
64.8
作者：
Galli, Stephen J.;Tsai, Mindy;Piliponsky, Adrian M.
通讯作者：
Piliponsky, Adrian M.